Shao-Lee Lin is stepping down as founding CEO of Acelyrin, a California drug developer that raised the largest biotech IPO in 2023 and subsequently ran into clinical hurdles with its lead immunology candidate.
Acelyrin disclosed the leadership shuffle on Thursday, and it also scratched its planned first-quarter earnings call. The biotech said it is “actively considering alternatives to further extend its cash runway.” As of March 31, it had $678.5 million in cash, equivalents and short-term marketable securities, which are slated to keep operations afloat into 2026.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.